PeptiDream (4587) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was ¥4,233 million, nearly flat year-over-year, with a core operating loss of ¥1,356 million and a net loss attributable to owners of ¥1,033 million, both increasing from the prior year.

• Radiopharmaceuticals business showed strong progress, with revenue up ¥122 million year-over-year and segment profit of ¥84 million, reversing a loss last year.

• Drug Discovery and Development segment revenue declined by ¥114 million year-over-year, with a segment loss of ¥1,428 million, up ¥473 million from the prior year.

• Significant R&D and pipeline activity in both radiopharmaceuticals and non-radiopharmaceuticals, with multiple clinical and preclinical programs advancing.

• Cash and cash equivalents decreased by ¥12.6 billion during the quarter, mainly due to tax payments and operating losses.

Financial highlights

• Q1 2025 revenue: ¥4,233 million (up ¥8 million year-over-year).

• Core operating loss: ¥1,356 million (increased by ¥362 million year-over-year).

• Net loss attributable to owners: ¥1,033 million (increased by ¥191 million year-over-year).

• Basic and diluted EPS: ¥(7.97), compared to ¥(6.50) in Q1 2024.

• Cash and cash equivalents at March 31, 2025: ¥35,477 million, down from ¥48,118 million at year-end.

Outlook and guidance

• FY2025 revenue forecast: ¥49,000 million (+5.0% year-over-year).

• Core operating profit forecast: ¥21,700 million (+2.2% year-over-year).

• Net profit attributable to owners forecast: ¥15,100 million (+0.6% year-over-year).

• No change to previously announced guidance.